PCN67 COST-EFFECTIVENESS ANALYSIS OF DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY IN PORTUGAL
Nov 1, 2019, 00:00 AM
10.1016/j.jval.2019.09.264
https://www.valueinhealthjournal.com/article/S1098-3015(19)32642-7/fulltext
Section Title :
Section Order :
10208
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32642-7&doi=10.1016/j.jval.2019.09.264